PH12012501683A1 - Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant - Google Patents
Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvantInfo
- Publication number
- PH12012501683A1 PH12012501683A1 PH1/2012/501683A PH12012501683A PH12012501683A1 PH 12012501683 A1 PH12012501683 A1 PH 12012501683A1 PH 12012501683 A PH12012501683 A PH 12012501683A PH 12012501683 A1 PH12012501683 A1 PH 12012501683A1
- Authority
- PH
- Philippines
- Prior art keywords
- virus
- particle
- adjuvant
- composition
- amyloid beta
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 239000002671 adjuvant Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000002245 particle Substances 0.000 title abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
- 206010012289 Dementia Diseases 0.000 abstract 2
- 241001515965 unidentified phage Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10158273 | 2010-03-29 | ||
| US36169710P | 2010-07-06 | 2010-07-06 | |
| PCT/EP2011/054735 WO2011120924A1 (en) | 2010-03-29 | 2011-03-28 | Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12012501683A1 true PH12012501683A1 (en) | 2012-11-05 |
Family
ID=42285305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2012/501683A PH12012501683A1 (en) | 2010-03-29 | 2011-03-28 | Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20130011431A1 (enExample) |
| EP (1) | EP2552489A1 (enExample) |
| JP (2) | JP6088422B2 (enExample) |
| KR (1) | KR20130018407A (enExample) |
| CN (2) | CN102834118A (enExample) |
| AR (1) | AR080810A1 (enExample) |
| AU (1) | AU2011234656B2 (enExample) |
| BR (1) | BR112012024708A2 (enExample) |
| CA (1) | CA2793580A1 (enExample) |
| CL (1) | CL2012002685A1 (enExample) |
| CO (1) | CO6630127A2 (enExample) |
| EC (1) | ECSP12012180A (enExample) |
| GT (1) | GT201200265A (enExample) |
| IL (1) | IL221540B (enExample) |
| MA (1) | MA34084B1 (enExample) |
| MX (1) | MX2012011340A (enExample) |
| NZ (1) | NZ601729A (enExample) |
| PE (1) | PE20130642A1 (enExample) |
| PH (1) | PH12012501683A1 (enExample) |
| RU (1) | RU2603486C2 (enExample) |
| SG (2) | SG183806A1 (enExample) |
| TN (1) | TN2012000431A1 (enExample) |
| TW (2) | TW201618806A (enExample) |
| WO (1) | WO2011120924A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3027205A4 (en) | 2013-07-28 | 2017-07-19 | Qantu Therapeutics, Inc. | Vaccine formulations that induce a th2 immune response |
| ES2651537T3 (es) * | 2014-04-29 | 2018-01-29 | Affiris Ag | Tratamiento y prevención de la enfermedad de Alzheimer (AD) |
| WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| WO2015165971A1 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| CN106659736A (zh) | 2014-04-29 | 2017-05-10 | 阿费里斯股份公司 | 阿尔茨海默病(ad)的治疗和预防 |
| EP3137097B1 (en) * | 2014-04-29 | 2023-06-21 | ADvantage Therapeutics, Inc. | Treatment and prevention of alzheimer's disease (ad) |
| ES2571055B1 (es) * | 2016-02-15 | 2016-12-28 | Araclon Biotech, S.L. | Conjugado amiloide y usos y procedimientos del mismo |
| CA3150482A1 (en) | 2019-09-16 | 2021-03-25 | Amgen Inc. | Method for external sterilization of drug delivery device |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU201906B (en) | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
| US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
| FR2734484B1 (fr) * | 1995-05-24 | 1997-06-27 | Pasteur Merieux Serums Vacc | Composition vaccinale liquide et procede de fabrication |
| CA2295740A1 (en) * | 1997-07-08 | 1999-01-21 | Chiron Corporation | Use of submicron oil-in-water emulsions with dna vaccines |
| AU2002330681C1 (en) * | 2001-07-26 | 2015-04-02 | Glaxosmithkline Biologicals S.A. | Vaccines comprising aluminium adjuvants and histidine |
| DK1524994T3 (da) * | 2002-07-19 | 2011-08-15 | Cytos Biotechnology Ag | Vaccinesammensætninger indeholdende amyloid beta 1-6-antigen-arrays |
| CN100409896C (zh) * | 2003-03-31 | 2008-08-13 | 姚志彬 | 一种老年性痴呆疫苗及其制备方法 |
| MX2007003171A (es) * | 2004-09-21 | 2007-05-23 | Cytos Biotechnology Ag | Particulas tipo virus que comprenden una proteina de fusion de la proteina de cubierta de ap205 y un polipeptido antigenico. |
| GB0424563D0 (en) * | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| CN101318015A (zh) * | 2008-06-25 | 2008-12-10 | 中山大学 | 老年性痴呆重组蛋白疫苗及其制备方法 |
-
2011
- 2011-03-28 BR BR112012024708A patent/BR112012024708A2/pt not_active Application Discontinuation
- 2011-03-28 CN CN2011800162176A patent/CN102834118A/zh active Pending
- 2011-03-28 TW TW104125184A patent/TW201618806A/zh unknown
- 2011-03-28 KR KR1020127025613A patent/KR20130018407A/ko not_active Ceased
- 2011-03-28 EP EP11711322A patent/EP2552489A1/en not_active Withdrawn
- 2011-03-28 WO PCT/EP2011/054735 patent/WO2011120924A1/en not_active Ceased
- 2011-03-28 CN CN201410789825.6A patent/CN104436212A/zh active Pending
- 2011-03-28 PE PE2012001825A patent/PE20130642A1/es not_active Application Discontinuation
- 2011-03-28 AU AU2011234656A patent/AU2011234656B2/en not_active Ceased
- 2011-03-28 AR ARP110101001A patent/AR080810A1/es not_active Application Discontinuation
- 2011-03-28 SG SG2012060554A patent/SG183806A1/en unknown
- 2011-03-28 PH PH1/2012/501683A patent/PH12012501683A1/en unknown
- 2011-03-28 MX MX2012011340A patent/MX2012011340A/es active IP Right Grant
- 2011-03-28 US US13/578,017 patent/US20130011431A1/en not_active Abandoned
- 2011-03-28 NZ NZ601729A patent/NZ601729A/xx not_active IP Right Cessation
- 2011-03-28 RU RU2012145734/15A patent/RU2603486C2/ru not_active IP Right Cessation
- 2011-03-28 MA MA35241A patent/MA34084B1/fr unknown
- 2011-03-28 TW TW100110650A patent/TW201138805A/zh unknown
- 2011-03-28 JP JP2013501791A patent/JP6088422B2/ja not_active Expired - Fee Related
- 2011-03-28 CA CA2793580A patent/CA2793580A1/en not_active Abandoned
- 2011-03-28 SG SG10201505374TA patent/SG10201505374TA/en unknown
-
2012
- 2012-08-20 IL IL221540A patent/IL221540B/en not_active IP Right Cessation
- 2012-08-30 TN TNP2012000431A patent/TN2012000431A1/en unknown
- 2012-09-25 EC ECSP12012180 patent/ECSP12012180A/es unknown
- 2012-09-26 GT GT201200265A patent/GT201200265A/es unknown
- 2012-09-27 CL CL2012002685A patent/CL2012002685A1/es unknown
- 2012-10-01 CO CO12171902A patent/CO6630127A2/es unknown
-
2014
- 2014-08-11 US US14/456,562 patent/US20140348871A1/en not_active Abandoned
-
2015
- 2015-06-26 US US14/751,492 patent/US20150297692A1/en not_active Abandoned
- 2015-12-17 US US14/972,187 patent/US20160101167A1/en not_active Abandoned
-
2016
- 2016-06-09 JP JP2016115660A patent/JP2017008035A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12012501683A1 (en) | Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| UA109868C2 (ru) | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) | |
| WO2012024530A3 (en) | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods | |
| WO2013188792A3 (en) | Neuroactive steroids, compositions, and uses thereof | |
| JO3776B1 (ar) | التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf | |
| MX2012007806A (es) | Composiciones farmaceuticas para administracion oral de peptidos de insulina. | |
| MX2011003473A (es) | Composiciones para el cuidado bucal. | |
| EP4414376A3 (en) | Novel depsipeptide and uses thereof | |
| WO2013061004A8 (fr) | Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines | |
| WO2011017502A3 (en) | Linaclotide-containing formulations for oral administration | |
| MX347734B (es) | Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas. | |
| MX349948B (es) | Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae. | |
| GEP20115293B (en) | Isolated extract of walnuts, process for its obtaining and its use | |
| MX2015001917A (es) | Composiciones farmaceuticas de memantina. | |
| MX2012001691A (es) | Composiciones de linaclotida que se desintegran oralmente. | |
| PH12013502179A1 (en) | Oral care compositions | |
| WO2008035380A3 (en) | An improved process for the preparation of high purity formoterol and its pharmaceutically acceptable salts | |
| BR112012013199A2 (pt) | composto, composição farmacêutica, e , uso de um composto | |
| AU2011263493A8 (en) | Crystalline forms of thalidomide and processes for their preparation | |
| TN2012000174A1 (en) | Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease | |
| WO2014167579A3 (en) | Stable pharmaceutical compositions of tadalafil | |
| WO2011089576A3 (en) | Novel compositions for reducing abeta 42 production and their use in treating alzheimer's disease (ad) | |
| MY197454A (en) | Non-enteric pharmaceutical composition comprising crofelemer | |
| PH12013502080A1 (en) | Modified release pharmaceutical compositions of desvenlafaxine |